Hanmi Pharma gained one big deal with Roche this week, but lost another tie-up with Boehringer--and investors didn't like it one bit.

Vertex won a label expansion for cystic fibrosis combo Orkambi late Wednesday--but, as expected, the company lowered its full-year guidance for the med, too.…

Over 7 years, GlaxoSmithKline’s investment in Aspen Pharmacare grew in value sixfold. But that run has come to an end, as GSK wrapped up its final stake sale…

GlaxoSmithKline CEO-to-be Emma Walmsley will leave a chair vacant at the top of its key consumer health JV, and stepping in to take it is Brian McNamara, a…

Novo Nordisk, pressured by U.S. payers and stepped-up competition in its signature diabetes market, will lay off 1,000 people worldwide to cut costs and…

Kyowa Hakko Kirin is rolling out the psoriasis med brodalumab this week in Japan, its first world market, but it faces a tough road ahead.

It’s Day 2 of the 7-day district court hearing over the patent protection on Teva’s 40-mg Copaxone, and so far, things aren’t looking great for the drugmaker.

Mylan has been fighting for more than a year to block Teva’s generic EpiPen. But all along EpiPen itself has been classified as a generic drug for Medicaid…